Medikit (7749) Q4 2025 earnings summary

Executive summary

• Net sales increased by 3.2% year-over-year to ¥22,553 million for the fiscal year ended March 31, 2025.

• Operating profit declined by 4.1% year-over-year to ¥4,486 million, and ordinary profit decreased by 2.6% to ¥4,658 million.

• Profit attributable to owners of parent fell 1.8% year-over-year to ¥3,013 million.

• Comprehensive income decreased by 8.2% year-over-year to ¥3,079 million.

Financial highlights

• Gross profit was ¥8,668 million, down slightly from the previous year.

• Operating margin declined to 19.9% from 21.4% year-over-year.

• Basic earnings per share rose to ¥204.55 from ¥187.95 year-over-year.

• Equity-to-asset ratio remained strong at 86.1%.

• Cash and cash equivalents at year-end were ¥17,059 million, down from ¥19,111 million.

Outlook and guidance

• Forecast for fiscal year ending March 31, 2026: net sales of ¥24,000 million (+6.4% YoY), operating profit of ¥4,500 million (+0.3% YoY), and profit attributable to owners of parent of ¥2,924 million (−3.0% YoY).

• Dividend forecast for FY2026 is ¥100 per share, up from ¥90 in FY2025.